AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 68 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,828,982 | +55.3% | 4,059,894 | 0.0% | 0.10% | +96.0% |
| Q1 2023 | $1,177,369 | -35.5% | 4,059,894 | 0.0% | 0.05% | -35.1% |
| Q4 2022 | $1,826,546 | -14.5% | 4,059,894 | 0.0% | 0.08% | -13.5% |
| Q3 2022 | $2,136,000 | +4.1% | 4,059,894 | 0.0% | 0.09% | +14.1% |
| Q2 2022 | $2,051,000 | -78.0% | 4,059,894 | 0.0% | 0.08% | -72.6% |
| Q1 2022 | $9,338,000 | -23.5% | 4,059,894 | +57.9% | 0.28% | +20.8% |
| Q4 2021 | $12,212,000 | -28.8% | 2,571,000 | +19.2% | 0.24% | -18.3% |
| Q3 2021 | $17,154,000 | +17.7% | 2,157,727 | +3.0% | 0.29% | +32.6% |
| Q2 2021 | $14,575,000 | +34.6% | 2,094,100 | +53.2% | 0.22% | +36.2% |
| Q1 2021 | $10,827,000 | +81.3% | 1,367,073 | +80.2% | 0.16% | +88.2% |
| Q4 2020 | $5,971,000 | +59.2% | 758,739 | +43.4% | 0.08% | +25.0% |
| Q3 2020 | $3,751,000 | +243.8% | 529,100 | +348.7% | 0.07% | +195.7% |
| Q2 2020 | $1,091,000 | – | 117,929 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 340,679 | $3,604,000 | 1.39% |
| Nantahala Capital Management | 2,213,052 | $23,414,000 | 0.95% |
| SCP Investment, LP | 156,137 | $1,652,000 | 0.82% |
| SPHERA FUNDS MANAGEMENT LTD. | 509,118 | $5,386,000 | 0.74% |
| DELTEC ASSET MANAGEMENT LLC | 151,781 | $1,606,000 | 0.32% |
| Rock Springs Capital Management LP | 650,000 | $6,877,000 | 0.26% |
| Orbimed Advisors | 1,865,524 | $19,737,000 | 0.24% |
| Baker Brothers Advisors | 1,387,872 | $14,684,000 | 0.11% |
| EAM Investors, LLC | 56,726 | $600,000 | 0.10% |
| Stanley-Laman Group, Ltd. | 35,036 | $371,000 | 0.08% |